Objective To investigate current status of economic toxicity in patients with pulmonary carcinoma after CyberKnife therapy and its influencing factors. Methods A total of 220 patients with pulmonary carcinoma after CyberKnife therapy were selected as the research subjects. General data inventory, Comprehensive Scores for Financial Toxicity Based on the Patient⁃Reported Outcome Measure (COST⁃PROM), Social Support Rating Scale (SSRS), Fear of Progression Questionnaire⁃Short Form (FOP⁃Q⁃SF), and Functional Assessment of Cancer Therapy⁃General (FACT⁃G) were employed to investigate. Multiple linear regression model was adopted to analyze the influencing factors for economic toxicity of patients with pulmonary carcinoma after CyberKnife therapy. Results The total score of COST⁃PROM of 220 patients with pulmonary carcinoma after CyberKnife therapy was 17.38±4.28, and 90.9% of the patients had economic toxicity, as well as 84.1% of the patients were in mild to moderate economic toxicity. There were statistically significant differences in the total score of COST⁃PROM of pulmonary carcinoma patients with different fertility status, educational level, marital status, working status, family per capita monthly income, knowledge of treatment cost, course of disease and pathological types after CyberKnife therapy (P<0.05). After CyberKnife therapy in patients with pulmonary carcinoma, the total score of COST⁃PROM positively correlated with the total scores of SSRS and FACT⁃G, and negatively correlated with the total score of FOP⁃Q⁃SF (P<0.05). The results of multiple linear regression analysis revealed that working status, family per capita monthly income, total score of FOP⁃Q⁃SF and total score of SSRS were the influencing factors for economic toxicity of patients with pulmonary carcinoma after CyberKnife therapy (P<0.05). Conclusion The economic toxicity of patients with pulmonary carcinoma after CyberKnife therapy is ubiquitous and generally mild to moderate, and is affected by factors such as working status, family per capita monthly income, social support and fear of disease progression.